Virtual Library
Start Your Search
Q. Guo
Author of
-
+
P2.03a - Poster Session with Presenters Present (ID 464)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03a-035 - Down-Regulation of βIII-Tubulin and bFGF Sensitizes Non–Small Cell Lung Carcinoma A549/Taxol Cells Lines to Taxol (ID 4755)
14:30 - 14:30 | Author(s): Q. Guo
- Abstract
Background:
Despite the success of taxol as an anti-tumor agent, the development of acquired resistance greatly limits its efficacy. A biomarker to predict sensitivity is greatly needed for this agent. The aim of this study was to explore the correlation between the expression of βIII -tubulin/bFGF and taxol chemosensitivity in non–small cell lung carcinoma (NSCLC) A549/Taxol cell lines.
Methods:
Small interfering RNA (siRNA) was utilized to down-regulate the expression of the two genes βIII-tubulin and bFGF in lung adenocarcinoma A549/Taxol cell lines. Interference effect was detected at mRNA level and protein level respectively by Real Time PCR (RT-PCR) and Western-blot. The cell sensitivity to taxol was examined using MTT assay. Furthermore, apoptosis and cell cycle of A549/ taxol cells were tested by flow cytometry.
Results:
βIII-tubulin and bFGF expression at mRNA level and protein level in NSCLC A549/Taxol cell lines after siRNA transfection were significantly lower than those before transfection. The sensitivity of A549/Taxol cells to taxol got a raise by down-regulating βIII-tubulin and bFGF expression. Moreover, it was also found that down-regulation of the two genes significantly increased cell apoptosis and G2/M phase cells percentage.
Conclusion:
Down-regulation of either βIII-tubulin or bFGF can sensitize A549/Taxol cells to taxol in vitro. It might be achieved through regulating cell apoptosis and cell cycle. It revealed that the two genes βIII-tubulin and bFGF play critical roles in mediating response to taxol and may serve as novel potential predictive factors for NSCLC therapy.
